Global Duloxetine Intermediate & Atorvastatin Intermediates Market Research Report Forecast to 2023

Array
(
    [id] => 1649600
    [discount] => PDF-18-ENTERPRISE WIDE LICENCE-20------
    [isbn] => 
    [title] => Global Duloxetine Intermediate & Atorvastatin Intermediates Market Research Report Forecast to 2023
    [upcommingtext] => 
    [seo_url] => global-duloxetine-intermediate-and-atorvastatin-intermediates-market-research-report-forecast
    [shortdesc] => 
    [meta_title] => Global Duloxetine Intermediate & Atorvastatin Intermediates Market Research Report Forecast to 2023
    [keyword] => Global Duloxetine Intermediate & Atorvastatin Intermediates Market Research Report Forecast to 2023
    [description] => Global Duloxetine Intermediate & Atorvastatin Intermediates Market Research Report Forecast to 2023 market research report available in single user pdf license with Aarkstore Enterprise at USD 4450
    [curr] => USD
    [category] => 1200
    [publisher] => 182
    [published_date] => 2019-06-24
    [country] => 230
    [author_name] => 
    [page_num] => 106
    [abstract] => 

Global Duloxetine Intermediate & Atorvastatin Intermediates Market: Information by Intermediate Type (Duloxetine Intermediates and Atorvastatin Intermediates) and Region (North America, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2023
 

Market analysis

Duloxetine intermediate is a serotonin-norepinephrine reuptake inhibitor (SNRI) which is generally affirmed for the treatment of stress urinary incontinence in ladies, major depressive disorder (MDD), and other types of chronic ailments. The atorvastatin intermediate is generally utilized in bringing down the cholesterol level and counteracts cardiovascular infections. The expanding predominance of major depressive disorder (MDD) and the developing significance of generics. Also, expanding interest for atorvastatin middle of the road and rising occurrence of unending sicknesses. In any case, rising medicinal services cost and negative medication value control strategies crosswise over different nations are probably going to limit showcase development. Atorvastatin Intermediates Manufacturers, Duloxetine Intermediate Manufacturers, Contract Research Organizations, Pharmaceutical Companies, Contract Manufacturing Organizations are some of the intended audience in the Global Duloxetine Intermediate & Atorvastatin Intermediates Market. The Global Duloxetine Intermediate and Atorvastatin Intermediates Market are required to enlist a CAGR of 4.04% to reach USD 73,546.68 thousand by 2023.

Market segmentation

 

The Global Duloxetine Intermediate and Atorvastatin Intermediates Market is classified on the basis of its type and regional demand. Based on its type, the Global Duloxetine Intermediate and Atorvastatin Intermediates Market is segmented into Atorvastatin Intermediates and Duloxetine Intermediates.
Regional analysis

Geographically, the Global Duloxetine Intermediate and Atorvastatin Intermediates Market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Afine Chemicals Ltd (China), Shodhana Laboratories (India), Fluorochem Ltd (UK), Chiral BioSciences Ltd (India) and Tokyo Chemical Industry Co., Ltd (Japan), Jiangxi Aifeimu Technology Co., Ltd (China), Zhejiang Jiuzhou Pharmaceutical Co., Ltd (China), Jigs Chemicals (India), Manus Aktteva (India), Arch Pharmalabs (India), among others are some of the major players in the Global Duloxetine Intermediate and Atorvastatin Intermediates Market.
 

[table_of_contents] =>



1 Executive Summary
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.3 Assumptions & Limitations
2.3.1 Assumptions
2.3.2 Limitations
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Top-Down & Bottom-Up Approach
3.6 Market forecast
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Rising Prevalence of Major Depressive Disorder (MDD)
4.2.2 Growing Importance of Generics
4.2.3 Increasing Demand for Atorvastatin Intermediate
4.2.4 Rising Incidence of Chronic Diseases
4.3 Restraints
4.3.1 Rising Healthcare Cost
4.3.2 Unfavorable Drug Price Control Policies Across Various Countries
4.4 Opportunities
4.4.1 Entering Developing Economies
4.5 Market Trends
4.5.1 Introduction of Innovative Drugs
4.6 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Supply Chain Analysis
5.1.1 R&D
5.1.2 Manufacturing
5.1.3 Distribution & Sales
5.1.4 Post-Sales Monitoring
5.2 Porter’s Five Forces Analysis
5.2.1 Threat of New Entrants
5.2.2 Bargaining Power of Suppliers
5.2.3 Threat of Substitutes
5.2.4 Bargaining Power of Buyers
5.2.5 Intense Rivalry
5.3 Investment Opportunities
5.4 Pricing Analysis
5.5 Product Pipeline Analysis
5.5.1 Overview
5.5.2 Duloxetine (Cymbalta) for Dysthymic Disorder and Depressive Disorder NOS
5.5.3 Effect of Duloxetine for the Treatment of Chronic Pain due to Osteoarthritis
5.5.4 Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients with Chronic Pain
5.5.5 Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents with Depressive Disorder
5.5.6 Perioperative Duloxetine for Pain Management After Laparoscopic Hysterectomy
5.5.7 Atorvastatin Calcium Tablets, 40 mg
5.5.8 Actual Use Trial of Atorvastatin Calcium 10 mg
5.5.9 Atorvastatin Vs. Simvastatin in the Prevention of Coronary Heart Disease (CHD) in Patients with Known CHD
5.5.10 Atorvastatin for the Treatment of Pulmonary Sarcoidosis
5.5.11 Atorvastatin for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women with Elevated Low-density Lipoprotein (LDL) Cholesterol
5.6 Specifications & Purity Requirements
5.7 Patent Analysis
5.7.1 Overview
5.7.2 Patent Analysis for the Process of Preparation of Duloxetine Intermediate and Atorvastatin Intermediate
5.7.2.1 Process for the Preparation of Duloxetine Hydrochloride and its Precursors
5.7.2.2 Process for Preparing 4-Chloro-3-Hydroxybutanoic Acid Ester
5.8 Regulatory Scenario
5.9 Manufacturing Processes
5.9.1 Duloxetine Intermediate
5.9.2 Atorvastatin Intermediate
5.1 Key Customers
6 Global Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
6.1 Overview
6.2 Duloxetine Intermediates
6.3 Atorvastatin Intermediates
7 Global Duloxetine Intermediate & Atorvastatin Intermediates Market, By Region
7.1 Overview
7.2 Americas
7.2.1 North America
7.2.1.1 US
7.2.1.2 Canada
7.2.2 Latin America
7.3 Europe
7.3.1 Western Europe
7.3.1.1 Germany
7.3.1.2 France
7.3.1.3 UK
7.3.1.4 Spain
7.3.1.5 Italy
7.3.1.6 Rest of Western Europe
7.3.2 Eastern Europe
7.4 Asia-Pacific
7.4.1 China
7.4.2 India
7.4.3 Japan
7.4.4 Rest of Asia-Pacific
7.5 Middle East & Africa
7.5.1 Middle East
7.5.2 Africa
8 Competitive Landscape
8.1 Introduction
9 Company Profiles
9.1 Jiangxi Aifeimu Technology Co., Ltd
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Products/Services Offered
9.1.4 Key Developments
9.1.5 SWOT Analysis
9.1.6 Key Strategies
9.2 Zhejiang Jiuzhou Pharmaceutical Co., Ltd
9.2.1 Company Overview
9.2.2 Financial Overview
9.2.3 Products/Services Offered
9.2.4 Key Developments
9.2.5 SWOT Analysis
9.2.6 Key Strategies
9.3 Jigs Chemicals
9.3.1 Company Overview
9.3.2 Financial Overview
9.3.3 Products/Services Offered
9.3.4 Key Developments
9.3.5 SWOT Analysis
9.3.6 Key Strategies
9.4 Manus Aktteva
9.4.1 Company Overview
9.4.2 Financial Overview
9.4.3 Products/Services Offered
9.4.4 Key Developments
9.4.5 SWOT Analysis
9.4.6 Key Strategies
9.5 Arch Pharmalabs
9.5.1 Company Overview
9.5.2 Financial Overview
9.5.3 Products/Services Offered
9.5.4 Key Developments
9.5.5 SWOT Analysis
9.5.6 Key Strategies
9.6 Afine Chemicals Ltd
9.6.1 Company Overview
9.6.2 Financial Overview
9.6.3 Products/Services Offered
9.6.4 Key Developments
9.6.5 SWOT Analysis
9.6.6 Key Strategies
9.7 Shodhana Laboratories
9.7.1 Company Overview
9.7.2 Financial Overview
9.7.3 Products/Services Offered
9.7.4 Key Developments
9.7.5 SWOT Analysis
9.7.6 Key Strategies
9.8 Fluorochem Ltd
9.8.1 Company Overview
9.8.2 Financial Overview
9.8.3 Products/Services Offered
9.8.4 Key Developments
9.8.5 SWOT Analysis
9.8.6 Key Strategies
9.9 Chiral Bio Sciences Ltd
9.9.1 Company Overview
9.9.2 Financial Overview
9.9.3 Products/Services Offered
9.9.4 Key Developments
9.9.5 SWOT Analysis
9.9.6 Key Strategies
9.1 Tokyo Chemical Industry Co., Ltd
9.10.1 Company Overview
9.10.2 Financial Overview
9.10.3 Products/Services Offered
9.10.4 Key Developments
9.10.5 SWOT Analysis
9.10.6 Key Strategies
10 Appendix
10.1 References
10.2 Related Reports
 

[list_of_tables] =>


TABLE 1 MARKET SYNOPSIS
TABLE 2 PRIMARY INTERVIEWS
TABLE 3 GLOBAL DULOXETINE INTERMEDIATE ((S)-(-)-N,N-DIMETHYL-3-HYDROXY-3-(2-THIENYL)PROPANAMINE (CAS NO. 132335-44-5))AVERAGE SELLING PRICE (ASP), BY REGION, 2015-2023 (USD/KG)
TABLE 4 GLOBAL (-)-ETHYL 4-CHLORO-3-HYDROXYBUTYRATE (CAS NO. 86728-85-0) AVERAGE SELLING PRICE (ASP), BY REGION, 2015-2023 (USD/KG)
TABLE 5 GLOBAL (3R)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER (CAS NO. 141942-85-0) AVERAGE SELLING PRICE (ASP), BY REGION, 2015-2023 (USD/KG)
TABLE 6 GLOBAL 1,3-DIOXANE-4-ACETIC ACID, 6-(CYANOMETHYL)-2,2-DIMETHYL-, 1,1-DIMETHYLETHYL ESTER, (4R,6R) (CAS NO. 125971-94-0) AVERAGE SELLING PRICE (ASP), BY REGION, 2015-2023 (USD/KG)
TABLE 7 CLINICAL TRIALS
TABLE 8 PATENT ANALYSIS FOR GLOBAL DULOXETINE & ATORVASTATIN DRUGS
TABLE 9 PROMINENT KEY CUSTOMERS FOR DULOXETINE INTERMEDIATE AND ATORVASTATIN INTERMEDIATES
TABLE 10 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 11 GLOBAL ATORVASTATIN INTERMEDIATES MARKET, BY ATORVASTATIN INTERMEDIATES TYPE, 2015–2023 (USD THOUSAND)
TABLE 12 GLOBAL DULOXETINE INTERMEDIATE ((S)-(-)-N,N-DIMETHYL-3-HYDROXY-3-(2-THIENYL)PROPANAMINE (CAS NO. 132335-44-5)) MARKET VOLUME, BY REGION 2015-2023 (TONS)
TABLE 13 GLOBAL DULOXETINE INTERMEDIATE ((S)-(-)-N,N-DIMETHYL-3-HYDROXY-3-(2-THIENYL)PROPANAMINE (CAS NO. 132335-44-5)) MARKET VOLUME, BY COUNTRY 2015-2023 (TONS)
TABLE 14 GLOBAL (-)-ETHYL 4-CHLORO-3-HYDROXYBUTYRATE (CAS NO. 86728-85-0) MARKET VOLUME, BY ERGION 2015-2023 (TONS)
TABLE 15 GLOBAL (-)-ETHYL 4-CHLORO-3-HYDROXYBUTYRATE (CAS NO. 86728-85-0) MARKET VOLUME, BY COUNTRY 2015-2023 (TONS)
TABLE 16 GLOBAL (3R)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER (CAS NO. 141942-85-0) MARKET VOLUME, BY REGION 2015-2023 (TONS)
TABLE 17 GLOBAL (3R)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER (CAS NO. 141942-85-0) MARKET VOLUME, BY COUNTRY 2015-2023 (TONS)
TABLE 18 GLOBAL 1,3-DIOXANE-4-ACETIC ACID, 6-(CYANOMETHYL)-2,2-DIMETHYL-, 1,1-DIMETHYLETHYL ESTER, (4R,6R) (CAS NO. 125971-94-0) MARKET VOLUME, BY REGION 2015-2023 (TONS)
TABLE 19 GLOBAL 1,3-DIOXANE-4-ACETIC ACID, 6-(CYANOMETHYL)-2,2-DIMETHYL-, 1,1-DIMETHYLETHYL ESTER, (4R,6R) (CAS NO. 125971-94-0) MARKET VOLUME, BY COUNTRY 2015-2023 (TONS)
TABLE 20 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR DULOXETINE INTERMEDIATE ((S)-(-)-N,N-DIMETHYL-3-HYDROXY-3-(2-THIENYL)PROPANAMINE (CAS NO. 132335-44-5)), BY REGION, 2015–2023 (USD THOUSAND)
TABLE 21 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, BY REGION, 2015-2023 (USD THOUSAND)
TABLE 22 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR (-)-ETHYL 4-CHLORO-3-HYDROXYBUTYRATE (CAS NO. 86728-85-0), BY REGION, 2015-2023 (USD THOUSAND)
TABLE 23 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR (3R)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER (CAS NO. 141942-85-0), BY REGION, 2015-2023 (USD THOUSAND)
TABLE 24 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR 1,3-DIOXANE-4-ACETIC ACID, 6-(CYANOMETHYL)-2,2-DIMETHYL-, 1,1-DIMETHYLETHYL ESTER, (4R,6R) (CAS NO. 125971-94-0), BY REGION, 2015-2023 (USD THOUSAND)
TABLE 25 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY REGION 2015-2023 (USD THOUSAND)
TABLE 26 AMERICAS DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY REGION 2015-2023 (USD THOUSAND)
TABLE 27 AMERICAS: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 28 AMERICAS: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 29 NORTH AMERICA: AMERICAS DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY COUNTRY, 2015–2023 (USD THOUSAND)
TABLE 30 NORTH AMERICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 31 NORTH AMERICA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 32 US: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 33 US: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 34 CANADA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 35 CANADA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 36 LATIN AMERICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 37 LATIN AMERICA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 38 EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY REGION, 2015–2023 (USD THOUSAND)
TABLE 39 EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 40 EUROPE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 41 WESTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY COUNTRY, 2015–2023 (USD THOUSAND)
TABLE 42 WESTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 43 WESTERN EUROPE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 44 GERMANY: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 45 GERMANY: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 46 FRANCE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 47 FRANCE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 48 UK: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 49 UK: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 50 SPAIN: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 51 SPAIN: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 52 ITALY: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 53 ITALY: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 54 REST OF WESTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 55 REST OF WESTERN EUROPE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 56 EASTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 57 EASTERN EUROPE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 58 ASIA-PACIFIC: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY COUNTRY, 2015–2023 (USD THOUSAND)
TABLE 59 ASIA-PACIFIC: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 60 ASIA-PACIFIC: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 61 CHINA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 62 CHINA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 63 INDIA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 64 INDIA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 65 JAPAN: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 66 JAPAN: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 67 REST OF ASIA-PACIFIC: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 68 REST OF ASIA-PACIFIC: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 69 MIDDLE EAST & AFRICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY REGION, 2015–2023 (USD THOUSAND)
TABLE 70 MIDDLE EAST & AFRICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 71 MIDDLE EAST & AFRICA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 72 MIDDLE EAST: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 73 MIDDLE EAST: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 74 AFRICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 75 AFRICA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 76 TOP MANUFACTURERS IN THE GLOBAL DULOXETINE INTERMEDIATE AND ATORVASTATIN INTERMEDIATES MARKET
 

[list_of_figures] =>



FIGURE 1 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET: MARKET STRUCTURE
FIGURE 2 RESEARCH PROCESS
FIGURE 3 SUPPLY CHAIN: GLOBAL DULOXETINE INTERMEDIATE AND ATORVASTATIN INTERMEDIATES MARKET
FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL DULOXETINE INTERMEDIATE AND ATORVASTATIN INTERMEDIATES MARKET
FIGURE 5 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY INTERMEDIATE TYPE, 2017(%)
FIGURE 6 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY ATORVASTATIN INTERMEDIATES TYPE, 2017(%)
FIGURE 7 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY INTERMEDIATE TYPE, 2017 & 2023 (USD THOUSAND)
FIGURE 8 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY ATORVASTATIN INTERMEDIATES TYPE, 2017 & 2023 (USD THOUSAND)
FIGURE 9 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION, 2017(%)
FIGURE 10 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION, 2017 & 2023 (USD THOUSAND)
FIGURE 11 AMERICAS DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION 2017 (%)
FIGURE 12 EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION, 2017 (%)
FIGURE 13 WESTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 14 ASIA-PACIFIC: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 15 MIDDLE EAST & AFRICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION, 2017 (%)
 

[sample_page] => [brochure] => [new_price] => PDF-4450-ENTERPRISE WIDE LICENCE-6250 )
discount aarkstore

Global Duloxetine Intermediate & Atorvastatin Intermediates Market: Information by Intermediate Type (Duloxetine Intermediates and Atorvastatin Intermediates) and Region (North America, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2023
 

Market analysis

Duloxetine intermediate is a serotonin-norepinephrine reuptake inhibitor (SNRI) which is generally affirmed for the treatment of stress urinary incontinence in ladies, major depressive disorder (MDD), and other types of chronic ailments. The atorvastatin intermediate is generally utilized in bringing down the cholesterol level and counteracts cardiovascular infections. The expanding predominance of major depressive disorder (MDD) and the developing significance of generics. Also, expanding interest for atorvastatin middle of the road and rising occurrence of unending sicknesses. In any case, rising medicinal services cost and negative medication value control strategies crosswise over different nations are probably going to limit showcase development. Atorvastatin Intermediates Manufacturers, Duloxetine Intermediate Manufacturers, Contract Research Organizations, Pharmaceutical Companies, Contract Manufacturing Organizations are some of the intended audience in the Global Duloxetine Intermediate & Atorvastatin Intermediates Market. The Global Duloxetine Intermediate and Atorvastatin Intermediates Market are required to enlist a CAGR of 4.04% to reach USD 73,546.68 thousand by 2023.

Market segmentation

 

The Global Duloxetine Intermediate and Atorvastatin Intermediates Market is classified on the basis of its type and regional demand. Based on its type, the Global Duloxetine Intermediate and Atorvastatin Intermediates Market is segmented into Atorvastatin Intermediates and Duloxetine Intermediates.
Regional analysis

Geographically, the Global Duloxetine Intermediate and Atorvastatin Intermediates Market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Afine Chemicals Ltd (China), Shodhana Laboratories (India), Fluorochem Ltd (UK), Chiral BioSciences Ltd (India) and Tokyo Chemical Industry Co., Ltd (Japan), Jiangxi Aifeimu Technology Co., Ltd (China), Zhejiang Jiuzhou Pharmaceutical Co., Ltd (China), Jigs Chemicals (India), Manus Aktteva (India), Arch Pharmalabs (India), among others are some of the major players in the Global Duloxetine Intermediate and Atorvastatin Intermediates Market.
 



1 Executive Summary
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.3 Assumptions & Limitations
2.3.1 Assumptions
2.3.2 Limitations
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Top-Down & Bottom-Up Approach
3.6 Market forecast
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Rising Prevalence of Major Depressive Disorder (MDD)
4.2.2 Growing Importance of Generics
4.2.3 Increasing Demand for Atorvastatin Intermediate
4.2.4 Rising Incidence of Chronic Diseases
4.3 Restraints
4.3.1 Rising Healthcare Cost
4.3.2 Unfavorable Drug Price Control Policies Across Various Countries
4.4 Opportunities
4.4.1 Entering Developing Economies
4.5 Market Trends
4.5.1 Introduction of Innovative Drugs
4.6 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Supply Chain Analysis
5.1.1 R&D
5.1.2 Manufacturing
5.1.3 Distribution & Sales
5.1.4 Post-Sales Monitoring
5.2 Porter’s Five Forces Analysis
5.2.1 Threat of New Entrants
5.2.2 Bargaining Power of Suppliers
5.2.3 Threat of Substitutes
5.2.4 Bargaining Power of Buyers
5.2.5 Intense Rivalry
5.3 Investment Opportunities
5.4 Pricing Analysis
5.5 Product Pipeline Analysis
5.5.1 Overview
5.5.2 Duloxetine (Cymbalta) for Dysthymic Disorder and Depressive Disorder NOS
5.5.3 Effect of Duloxetine for the Treatment of Chronic Pain due to Osteoarthritis
5.5.4 Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients with Chronic Pain
5.5.5 Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents with Depressive Disorder
5.5.6 Perioperative Duloxetine for Pain Management After Laparoscopic Hysterectomy
5.5.7 Atorvastatin Calcium Tablets, 40 mg
5.5.8 Actual Use Trial of Atorvastatin Calcium 10 mg
5.5.9 Atorvastatin Vs. Simvastatin in the Prevention of Coronary Heart Disease (CHD) in Patients with Known CHD
5.5.10 Atorvastatin for the Treatment of Pulmonary Sarcoidosis
5.5.11 Atorvastatin for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women with Elevated Low-density Lipoprotein (LDL) Cholesterol
5.6 Specifications & Purity Requirements
5.7 Patent Analysis
5.7.1 Overview
5.7.2 Patent Analysis for the Process of Preparation of Duloxetine Intermediate and Atorvastatin Intermediate
5.7.2.1 Process for the Preparation of Duloxetine Hydrochloride and its Precursors
5.7.2.2 Process for Preparing 4-Chloro-3-Hydroxybutanoic Acid Ester
5.8 Regulatory Scenario
5.9 Manufacturing Processes
5.9.1 Duloxetine Intermediate
5.9.2 Atorvastatin Intermediate
5.1 Key Customers
6 Global Duloxetine Intermediate & Atorvastatin Intermediates Market, By Intermediate Type
6.1 Overview
6.2 Duloxetine Intermediates
6.3 Atorvastatin Intermediates
7 Global Duloxetine Intermediate & Atorvastatin Intermediates Market, By Region
7.1 Overview
7.2 Americas
7.2.1 North America
7.2.1.1 US
7.2.1.2 Canada
7.2.2 Latin America
7.3 Europe
7.3.1 Western Europe
7.3.1.1 Germany
7.3.1.2 France
7.3.1.3 UK
7.3.1.4 Spain
7.3.1.5 Italy
7.3.1.6 Rest of Western Europe
7.3.2 Eastern Europe
7.4 Asia-Pacific
7.4.1 China
7.4.2 India
7.4.3 Japan
7.4.4 Rest of Asia-Pacific
7.5 Middle East & Africa
7.5.1 Middle East
7.5.2 Africa
8 Competitive Landscape
8.1 Introduction
9 Company Profiles
9.1 Jiangxi Aifeimu Technology Co., Ltd
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Products/Services Offered
9.1.4 Key Developments
9.1.5 SWOT Analysis
9.1.6 Key Strategies
9.2 Zhejiang Jiuzhou Pharmaceutical Co., Ltd
9.2.1 Company Overview
9.2.2 Financial Overview
9.2.3 Products/Services Offered
9.2.4 Key Developments
9.2.5 SWOT Analysis
9.2.6 Key Strategies
9.3 Jigs Chemicals
9.3.1 Company Overview
9.3.2 Financial Overview
9.3.3 Products/Services Offered
9.3.4 Key Developments
9.3.5 SWOT Analysis
9.3.6 Key Strategies
9.4 Manus Aktteva
9.4.1 Company Overview
9.4.2 Financial Overview
9.4.3 Products/Services Offered
9.4.4 Key Developments
9.4.5 SWOT Analysis
9.4.6 Key Strategies
9.5 Arch Pharmalabs
9.5.1 Company Overview
9.5.2 Financial Overview
9.5.3 Products/Services Offered
9.5.4 Key Developments
9.5.5 SWOT Analysis
9.5.6 Key Strategies
9.6 Afine Chemicals Ltd
9.6.1 Company Overview
9.6.2 Financial Overview
9.6.3 Products/Services Offered
9.6.4 Key Developments
9.6.5 SWOT Analysis
9.6.6 Key Strategies
9.7 Shodhana Laboratories
9.7.1 Company Overview
9.7.2 Financial Overview
9.7.3 Products/Services Offered
9.7.4 Key Developments
9.7.5 SWOT Analysis
9.7.6 Key Strategies
9.8 Fluorochem Ltd
9.8.1 Company Overview
9.8.2 Financial Overview
9.8.3 Products/Services Offered
9.8.4 Key Developments
9.8.5 SWOT Analysis
9.8.6 Key Strategies
9.9 Chiral Bio Sciences Ltd
9.9.1 Company Overview
9.9.2 Financial Overview
9.9.3 Products/Services Offered
9.9.4 Key Developments
9.9.5 SWOT Analysis
9.9.6 Key Strategies
9.1 Tokyo Chemical Industry Co., Ltd
9.10.1 Company Overview
9.10.2 Financial Overview
9.10.3 Products/Services Offered
9.10.4 Key Developments
9.10.5 SWOT Analysis
9.10.6 Key Strategies
10 Appendix
10.1 References
10.2 Related Reports
 


List Of Tables


TABLE 1 MARKET SYNOPSIS
TABLE 2 PRIMARY INTERVIEWS
TABLE 3 GLOBAL DULOXETINE INTERMEDIATE ((S)-(-)-N,N-DIMETHYL-3-HYDROXY-3-(2-THIENYL)PROPANAMINE (CAS NO. 132335-44-5))AVERAGE SELLING PRICE (ASP), BY REGION, 2015-2023 (USD/KG)
TABLE 4 GLOBAL (-)-ETHYL 4-CHLORO-3-HYDROXYBUTYRATE (CAS NO. 86728-85-0) AVERAGE SELLING PRICE (ASP), BY REGION, 2015-2023 (USD/KG)
TABLE 5 GLOBAL (3R)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER (CAS NO. 141942-85-0) AVERAGE SELLING PRICE (ASP), BY REGION, 2015-2023 (USD/KG)
TABLE 6 GLOBAL 1,3-DIOXANE-4-ACETIC ACID, 6-(CYANOMETHYL)-2,2-DIMETHYL-, 1,1-DIMETHYLETHYL ESTER, (4R,6R) (CAS NO. 125971-94-0) AVERAGE SELLING PRICE (ASP), BY REGION, 2015-2023 (USD/KG)
TABLE 7 CLINICAL TRIALS
TABLE 8 PATENT ANALYSIS FOR GLOBAL DULOXETINE & ATORVASTATIN DRUGS
TABLE 9 PROMINENT KEY CUSTOMERS FOR DULOXETINE INTERMEDIATE AND ATORVASTATIN INTERMEDIATES
TABLE 10 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 11 GLOBAL ATORVASTATIN INTERMEDIATES MARKET, BY ATORVASTATIN INTERMEDIATES TYPE, 2015–2023 (USD THOUSAND)
TABLE 12 GLOBAL DULOXETINE INTERMEDIATE ((S)-(-)-N,N-DIMETHYL-3-HYDROXY-3-(2-THIENYL)PROPANAMINE (CAS NO. 132335-44-5)) MARKET VOLUME, BY REGION 2015-2023 (TONS)
TABLE 13 GLOBAL DULOXETINE INTERMEDIATE ((S)-(-)-N,N-DIMETHYL-3-HYDROXY-3-(2-THIENYL)PROPANAMINE (CAS NO. 132335-44-5)) MARKET VOLUME, BY COUNTRY 2015-2023 (TONS)
TABLE 14 GLOBAL (-)-ETHYL 4-CHLORO-3-HYDROXYBUTYRATE (CAS NO. 86728-85-0) MARKET VOLUME, BY ERGION 2015-2023 (TONS)
TABLE 15 GLOBAL (-)-ETHYL 4-CHLORO-3-HYDROXYBUTYRATE (CAS NO. 86728-85-0) MARKET VOLUME, BY COUNTRY 2015-2023 (TONS)
TABLE 16 GLOBAL (3R)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER (CAS NO. 141942-85-0) MARKET VOLUME, BY REGION 2015-2023 (TONS)
TABLE 17 GLOBAL (3R)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER (CAS NO. 141942-85-0) MARKET VOLUME, BY COUNTRY 2015-2023 (TONS)
TABLE 18 GLOBAL 1,3-DIOXANE-4-ACETIC ACID, 6-(CYANOMETHYL)-2,2-DIMETHYL-, 1,1-DIMETHYLETHYL ESTER, (4R,6R) (CAS NO. 125971-94-0) MARKET VOLUME, BY REGION 2015-2023 (TONS)
TABLE 19 GLOBAL 1,3-DIOXANE-4-ACETIC ACID, 6-(CYANOMETHYL)-2,2-DIMETHYL-, 1,1-DIMETHYLETHYL ESTER, (4R,6R) (CAS NO. 125971-94-0) MARKET VOLUME, BY COUNTRY 2015-2023 (TONS)
TABLE 20 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR DULOXETINE INTERMEDIATE ((S)-(-)-N,N-DIMETHYL-3-HYDROXY-3-(2-THIENYL)PROPANAMINE (CAS NO. 132335-44-5)), BY REGION, 2015–2023 (USD THOUSAND)
TABLE 21 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, BY REGION, 2015-2023 (USD THOUSAND)
TABLE 22 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR (-)-ETHYL 4-CHLORO-3-HYDROXYBUTYRATE (CAS NO. 86728-85-0), BY REGION, 2015-2023 (USD THOUSAND)
TABLE 23 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR (3R)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER (CAS NO. 141942-85-0), BY REGION, 2015-2023 (USD THOUSAND)
TABLE 24 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, FOR 1,3-DIOXANE-4-ACETIC ACID, 6-(CYANOMETHYL)-2,2-DIMETHYL-, 1,1-DIMETHYLETHYL ESTER, (4R,6R) (CAS NO. 125971-94-0), BY REGION, 2015-2023 (USD THOUSAND)
TABLE 25 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY REGION 2015-2023 (USD THOUSAND)
TABLE 26 AMERICAS DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY REGION 2015-2023 (USD THOUSAND)
TABLE 27 AMERICAS: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 28 AMERICAS: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 29 NORTH AMERICA: AMERICAS DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY COUNTRY, 2015–2023 (USD THOUSAND)
TABLE 30 NORTH AMERICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 31 NORTH AMERICA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 32 US: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 33 US: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 34 CANADA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 35 CANADA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 36 LATIN AMERICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 37 LATIN AMERICA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 38 EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY REGION, 2015–2023 (USD THOUSAND)
TABLE 39 EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 40 EUROPE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 41 WESTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY COUNTRY, 2015–2023 (USD THOUSAND)
TABLE 42 WESTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 43 WESTERN EUROPE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 44 GERMANY: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 45 GERMANY: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 46 FRANCE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 47 FRANCE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 48 UK: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 49 UK: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 50 SPAIN: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 51 SPAIN: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 52 ITALY: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 53 ITALY: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 54 REST OF WESTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 55 REST OF WESTERN EUROPE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 56 EASTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 57 EASTERN EUROPE: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 58 ASIA-PACIFIC: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY COUNTRY, 2015–2023 (USD THOUSAND)
TABLE 59 ASIA-PACIFIC: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 60 ASIA-PACIFIC: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 61 CHINA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 62 CHINA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 63 INDIA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 64 INDIA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 65 JAPAN: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 66 JAPAN: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 67 REST OF ASIA-PACIFIC: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 68 REST OF ASIA-PACIFIC: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 69 MIDDLE EAST & AFRICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY REGION, 2015–2023 (USD THOUSAND)
TABLE 70 MIDDLE EAST & AFRICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 71 MIDDLE EAST & AFRICA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 72 MIDDLE EAST: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 73 MIDDLE EAST: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 74 AFRICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET, BY INTERMEDIATE TYPE, 2015–2023 (USD THOUSAND)
TABLE 75 AFRICA: ATORVASTATIN INTERMEDIATES MARKET, FOR ATORVASTATIN INTERMEDIATES TYPE, 2015-2023 (USD THOUSAND)
TABLE 76 TOP MANUFACTURERS IN THE GLOBAL DULOXETINE INTERMEDIATE AND ATORVASTATIN INTERMEDIATES MARKET
 


List Of Figures



FIGURE 1 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET: MARKET STRUCTURE
FIGURE 2 RESEARCH PROCESS
FIGURE 3 SUPPLY CHAIN: GLOBAL DULOXETINE INTERMEDIATE AND ATORVASTATIN INTERMEDIATES MARKET
FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL DULOXETINE INTERMEDIATE AND ATORVASTATIN INTERMEDIATES MARKET
FIGURE 5 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY INTERMEDIATE TYPE, 2017(%)
FIGURE 6 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY ATORVASTATIN INTERMEDIATES TYPE, 2017(%)
FIGURE 7 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY INTERMEDIATE TYPE, 2017 & 2023 (USD THOUSAND)
FIGURE 8 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY ATORVASTATIN INTERMEDIATES TYPE, 2017 & 2023 (USD THOUSAND)
FIGURE 9 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION, 2017(%)
FIGURE 10 GLOBAL DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION, 2017 & 2023 (USD THOUSAND)
FIGURE 11 AMERICAS DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION 2017 (%)
FIGURE 12 EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION, 2017 (%)
FIGURE 13 WESTERN EUROPE: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 14 ASIA-PACIFIC: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 15 MIDDLE EAST & AFRICA: DULOXETINE INTERMEDIATE & ATORVASTATIN INTERMEDIATES MARKET SHARE, BY REGION, 2017 (%)
 


2020 Global Transfusion Diagnostics Market for 40 Immunohematology and NAT Assays: Americas, EMEA, APAC--A 68-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation

This new 68-country report is available by region, country, market segment, section, or individual test. The report is designed to help current suppliers and potential market entrants identify and

USD 45000 View Report

Global Estrogen Replacement Therapy Market by Dosage Forms (Patches, Tablets, Gels/Creams, Suppositories, Implants And Injections), By Routes Of Administration (Oral, Topical, Subcutaneous Pellets, Injections, and Others), By End-User (Hospitals, Clinics, Pharmacy Store, and Others), and By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa), Forecast from 2020 to 2027

Global Estrogen Replacement Therapy Market by Dosage Forms (Patches, Tablets, Gels/Creams, Suppositories, Implants And Injections), By Routes Of Administration (Oral, Topical, Subcutaneous Pellets, Injections, and Others), By End-User (Hospitals, Clinics, Pharmacy Store, and Others), and By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa), Forecast from 2020 to 2027 market research report available in single user pdf license with Aarkstore Enterprise at USD 4950

USD 4950 View Report

Global Duloxetine Hydrochloride Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Duloxetine Hydrochloride is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end

USD 4000 View Report

Global Duloxetine hydrochloride(CAS 136434-34-9) Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Duloxetine hydrochloride(CAS 136434-34-9) is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the

USD 4000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available